SOURCE: Dynavax Technologies
BERKELEY, CA--(Marketwired - Oct 9, 2013) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the start of dosing in the first human clinical trial in its asthma program. Dynavax is conducting the trial under its collaboration agreement with AstraZeneca. The Phase 1 study will assess the safety of AZD1419, a proprietary TLR9 agonist developed by Dynavax on behalf of the collaboration. Up to approximately 45 healthy subjects will receive inhaled doses of AZD1419 or placebo in single and multiple ascending doses in the first part of the study, followed by up to approximately 24 patients with mild asthma in the second part of the study. Safety data from the first part of the study is expected in mid-2014.
AZD1419 was selected as a clinical candidate based on extensive preclinical studies conducted by Dynavax and AstraZeneca. These include a demonstration that AZD1419 can produce long lasting disease-modifying effects in a mouse model of atopic asthma.
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Dynavax's lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.